Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 2/20 | 0.60 |
| ▸ | F2 | P00734 | 16/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | F11 | P03951 | 2/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | F9 | P00740 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL23454676 | 1.00 | MASP2 (0.60) | MASP2F2CYP3A4F11F10 | |
| Trifluoroacetic Acid SCHEMBL30131490 | 0.90 | MASP2 (0.55) | MASP2F2CYP3A4F11F10 | |
| Trifluoroacetic Acid SCHEMBL23452472 | 0.89 | MASP2 (0.61) | MASP2F2CYP3A4F11F10 | |
| Trifluoroacetic Acid SCHEMBL29880513 | 0.89 | MASP2 (0.61) | MASP2F2CYP3A4F11F10 | |
| Trifluoroacetic Acid SCHEMBL28587648 | 0.89 | MASP2 (0.61) | MASP2F2CYP3A4F11F10 | |
| Trifluoroacetic Acid SCHEMBL28587649 | 0.89 | MASP2 (0.61) | MASP2F2CYP3A4F11F10 | |
| SCHEMBL23454674 | 0.87 | MASP2 (0.56) | MASP2F2CYP3A4F11F10 | |
| Trifluoroacetic Acid SCHEMBL28864384 | 0.85 | MASP2 (0.55) | MASP2F2CYP3A4F11F10 | |
| Trifluoroacetic Acid SCHEMBL29880440 | 0.84 | F2 (0.71) | MASP2F2CYP3A4F11F10 | |
| SCHEMBL25054253 | 0.83 | MASP2 (0.57) | MASP2F2CYP3A4F11F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2021113690-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210171512-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171512-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | MASP2 1/4885F2 4221/4885CYP3A4 4706/4885 |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | MASP2 1/4885F2 4221/4885CYP3A4 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.